Literature DB >> 16469344

Replicative fidelity of lentiviral vectors produced by transient transfection.

Meg M Laakso1, Richard E Sutton.   

Abstract

Previous investigations have estimated the human immunodeficiency virus type 1 (HIV) base pair substitution rate to be approximately 10(-4) to 10(-5) per round of viral replication, and HIV has been hypothesized to be more error-prone than other retroviruses. Using a single cycle reversion assay, we unexpectedly found that the reversion rates of HIV, avian leukosis virus and Moloney murine leukemia virus were the same, within statistical error. Because both the viral enzyme reverse transcriptase (RT) and cellular RNA polymerase II (RNAP) are required for viral replication, we hypothesized that the similar reversion rates actually reflect the intrinsic error rate of RNAP, which is the enzyme common to all three retroviruses in the reversion assay. To address this possibility, HIV vectors with the U3 region replaced by a reporter reversion cassette were constructed and vector supernatant produced by transient transfection. All single integrant revertant cell lines showed the identical mutations at both long terminal repeats. This indicates that either RNAP or another cellular enzyme is responsible for these reversions, or that HIV RT only makes errors during first strand synthesis. Additionally, when HIV particles were rescued from an integrated vector as opposed to being produced by transient transfection, the reversion rate was significantly lower, suggesting that one or more factors in the virus-producing cells plays a role in the fidelity of retroviral replication. These results have implications regarding the fidelity of the transgene after transient transfection production of lentiviral vector supernatants.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16469344     DOI: 10.1016/j.virol.2005.12.037

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  8 in total

Review 1.  Viral mutation rates.

Authors:  Rafael Sanjuán; Miguel R Nebot; Nicola Chirico; Louis M Mansky; Robert Belshaw
Journal:  J Virol       Date:  2010-07-21       Impact factor: 5.103

2.  Ex vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2Rγ(null) mice.

Authors:  Simon N Robinson; Paul J Simmons; Michael W Thomas; Nathalie Brouard; Jeannie A Javni; Suprita Trilok; Jae-Seung Shim; Hong Yang; David Steiner; William K Decker; Dongxia Xing; Leonard D Shultz; Barbara Savoldo; Gianpietro Dotti; Catherine M Bollard; Leonard Miller; Richard E Champlin; Elizabeth J Shpall; Patrick A Zweidler-McKay
Journal:  Exp Hematol       Date:  2012-02-02       Impact factor: 3.084

3.  RD2-MolPack-Chim3, a packaging cell line for stable production of lentiviral vectors for anti-HIV gene therapy.

Authors:  Anna Stornaiuolo; Bianca Maria Piovani; Sergio Bossi; Eleonora Zucchelli; Stefano Corna; Francesca Salvatori; Fulvio Mavilio; Claudio Bordignon; Gian Paolo Rizzardi; Chiara Bovolenta
Journal:  Hum Gene Ther Methods       Date:  2013-08-03       Impact factor: 2.396

4.  HIV-1 Transmission, Replication Fitness and Disease Progression.

Authors:  Tasha Biesinger; Jason T Kimata
Journal:  Virology (Auckl)       Date:  2008-07-14

5.  Mutation rates and intrinsic fidelity of retroviral reverse transcriptases.

Authors:  Luis Menéndez-Arias
Journal:  Viruses       Date:  2009-12-04       Impact factor: 5.048

Review 6.  Retroviral vectors for analysis of viral mutagenesis and recombination.

Authors:  Jonathan M O Rawson; Louis M Mansky
Journal:  Viruses       Date:  2014-09-24       Impact factor: 5.048

7.  Layer- and column-specific knockout of NMDA receptors in pyramidal neurons of the mouse barrel cortex.

Authors:  Rachel Aronoff; Carl Petersen
Journal:  Front Integr Neurosci       Date:  2007-11-30

8.  Early and transient reverse transcription during primary deltaretroviral infection of sheep.

Authors:  Carole Pomier; Maria T Sanchez Alcaraz; Christophe Debacq; Agnes Lançon; Pierre Kerkhofs; Lucas Willems; Eric Wattel; Franck Mortreux
Journal:  Retrovirology       Date:  2008-02-01       Impact factor: 4.602

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.